-
Kenya's economy faces climate change risks: World Bank
-
Israelis shelter with pets from threat of Iran missiles
-
Deadly strikes across Mideast as Iran vows revenge on slain security chief
-
Brussels to unveil 'EU Inc' pan-European company status
-
Brazil starts to restrict minors' access to social media
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Oscars audience drops, viewing figures show
-
Nvidia says restarting production of China-bound chips
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
Leftist New York mayor under pressure on Irish unity question
-
Iran vets friendly ships for Hormuz passage: trackers
-
Ships in Gulf risk shortages on board, industry warns
-
New particle discovered by Large Hadron Collider
-
US Fed expected to keep rates steady as Iran war impact looms
-
Kerr 'frustrated' at six-figure sum owed to him by Johnson's failed Grand Slam Track
-
Oil prices climb as fresh strikes target infrastructure
-
Belgian diplomat ordered to stand trial over 1961 Congo leader murder
-
War threatens Gulf's dugongs, turtles and birds
-
Germany targets oil firms to prevent wartime price gouging
-
EU to help reopen blocked oil pipeline in Ukraine
-
Cash handouts, fare hikes as Philippines battles soaring fuel costs
-
Indonesia weighs response to price pressures from Middle East war
-
In Hollywood, AI's no match for creativity, say top executives
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
Trump vows to 'take' Cuba as island reels from oil embargo
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Nvidia rides 'claw' craze with AI agent platform
-
Damaged Russian tanker has 700 tonnes of fuel on board: Moscow
-
Talks towards international panel to tackle 'inequality emergency' begin at UN
-
EU talks energy as oil price soars
-
Swiss government rejects proposal to limit immigration
-
Ingredients of life discovered in Ryugu asteroid samples
-
Why Iranian drones are hard to stop
-
France threatens to block funds for India over climate inaction
-
"So proud": Irish hometown hails Oscar winner Jessie Buckley
-
European bank battle heats up as UniCredit swoops for Commerzbank
-
Italian bank UniCredit makes bid for Germany's Commerzbank
-
AI to drive growth despite geopolitics, Taiwan's Foxconn says
-
Filipinas seek abortions online in largely Catholic nation
-
'One Battle After Another' wins best picture Oscar
-
South Koreans bask in Oscars triumph for 'KPop Demon Hunters'
-
'One Battle After Another' dominates Oscars
-
Norway's Oscar winner 'Sentimental Value': a failing father seeks redemption
-
Indonesia firms in palm oil fraud probe supplied fuel majors
-
Milan-Cortina Paralympics end as a 'beacon of unity'
-
It's 'Sinners' vs 'One Battle' as Oscars day arrives
-
Oscars night: latest developments
Nobel winner's ingenious chemistry could lead to cancer breakthroughs
"All kinds of crazy things" is how Carolyn Bertozzi, a 2022 Nobel laureate, describes her life's work. Actually performing "chemistry in cells and in people."
When she started her research in 1997, the Stanford professor was aiming only to observe the evolution of certain molecules on the surface of cancer cells.
Today, thanks to her discoveries, at least two companies -- including one she co-founded -- are developing innovative cancer treatments.
The multitude of applications made possible by her findings are impressive: delivering treatments with extreme precision, understanding better how drugs act inside the body, visualizing certain bacteria, to name a few.
"I can't even really enumerate them. The vast majority of those applications I would never have foreseen," she told AFP in an interview.
The Nobel Prize committee recognized Bertozzi's pioneering advances on Wednesday, making her only the eighth woman to win the chemistry prize, at just 55 years old.
- Lego pieces -
Her journey began when she found she had a passion for organic chemistry, while taking pre-medicine courses at Harvard.
The subject is notoriously -- many say fiendishly -- difficult, but she credits an "amazing professor," the late David Evans, for bringing it to life -- and changing the course of her life.
"I said, forget the med school thing. I'm going to be a chemist," said Bertozzi, whose sister is a professor of applied mathematics, and father a retired professor of physics.
After completing her post-doctorate and joining the faculty at UC Berkeley, she wanted to take a closer look at glycans: complex carbohydrates, or sugars, located on the surface of cells, which "go through structural changes" when they become cancerous.
At the time, "there was no tool to image sugars, like in a microscope, for example," she said.
She had an idea that would require two chemical substances that fit together perfectly, like pieces of lego.
The first lego is fed to cells via a sugar. The cell metabolizes it and places it on the tip of the glycan. The second piece of lego, a fluorescent molecule, is injected into the body.
The two lego pieces click together, and voila: hidden glycans reveal themselves under a microscope.
This technique is inspired by "click chemistry" developed independently by Denmark's Morten Meldal and American Barry Sharpless -- Bertozzi's co-winners. But their discoveries relied on using copper as a catalyst, which is toxic to the body.
One of Bertozzi's great leaps was achieving the same type of ultra-efficient reaction without copper.
The other tour de force: making it all happen without wreaking havoc with other processes in the body.
"The beauty of it is that you can take the two Legos and click them together, even if they're surrounded by millions of other very similar plastic toys," she explained.
She coined the term "bioorthogonal chemistry," meaning a reaction that doesn't interfere with other biochemical processes. Perfecting the technique took 10 years.
- 'Cycle of science' -
Researchers are now leveraging these breakthroughs to develop cancer treatments.
Glycans on cancer cells "are able to hide the cancer cell from the immune system -- and so your body can't fight it, it can't see it," she explains.
Using bioorthogonal chemistry, "we made a new type of medicine, which basically acts like a lawnmower," says Bertozzi.
The first lego attaches to the cancer cell's surface, and the second, which clips onto it, is equipped with an enzyme that "mows off the sugars as if they're just grass, it cuts the grass and the sugars fall off," she says with a smile.
The drug is currently being tested in the early stages of a clinical trial.
Another company is seeking to use bioorthogonal chemistry to better target cancer treatment. The first lego piece is injected into a tumor, then a second, which carries the drug, attaches itself and acts only on its target.
"So that allows the oncologist to treat the tumor and kill the tumor without exposing the person's entire body to a toxic chemical," she says.
"What the future holds is hopefully an impact in human health," says Bertozzi. "But the people who decide that more so than myself, are the students and postdocs that join my lab."
Hundreds of them, current and former, filled her email box with messages of congratulations this morning.
"That really is the cycle of science -- it's being mentored and then mentoring" she adds. And "mentoring students gives you an opportunity to amplify the impact of your science."
M.García--CPN